Compliance with ISO Standards has been continually maintained since it was first obtained in 2007.
Our cell-engineering delivery platform is clinically-proven, with growing use for the development of next-generation therapeutics.
An approved commercial immuno-therapy in Japan.
Referenced in multiple clinical trials, including several recently published/presented studies involving the expression of chimeric antigen receptors in autologous T cells.
Currently being used in more than 40 high-value cell therapy partnered programs covering cutting-edge fields of immuno-oncology, gene editing and regenerative medicine.
More than 15 programs have been licensed for clinical development and two programs for commercial use.
Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter